Oncology Corporate Profile
This company does not have any pipeline products
3/9/2016 11:01 am
(ECCO) Mar 9, 2016 - Radiotherapy to the whole breast is standard treatment after breast-conserving surgery for women with early breast cancer, even those who have a low risk of the disease returning in the breast (local relapse).
7/15/2015 11:03 am
(University of Wisconsin-Madison) July 14, 2015 - A diet that starves triple-negative breast cancer cells of an essential nutrient primes the cancer cells to be more easily killed by a targeted antibody treatment, UW Carbone Cancer Center scientists report in a recent publication.
7/18/2014 06:02 am
(PRWeb) July 17, 2014 - Dr. Mark Soloway, who has been appointed Chief of Urologic Oncology at Memorial Cancer Institute, will lead a new division focused on the care of bladder, prostate and kidney cancers, while also establishing a research program.
7/1/2014 06:02 am
(GEN) July 1, 2014 - The Phase II results are in for Agenus' autologous cancer vaccine Prophage: According to the immuno-oncology firm, the single-arm, multi-institutional, open-label study showed that patients with newly diagnosed glioblastoma multiforme (GBM) who received Prophage in addition to the standard of care treatment lived nearly twice as long as expected.
7/1/2014 01:05 am
(Reuters) July 1, 2014 - Agenus Inc said its experimental cancer vaccine helped brain tumor patients live nearly twice as long compared with those who received standard of care treatment.
6/2/2014 01:03 pm
(GTx) June 2, 2014 - GTx, Inc. today announced positive results from a Phase 2, proof-of-concept, open-label clinical study evaluating enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the treatment of patients with androgen receptor (AR) positive and estrogen receptor (ER) positive metastatic breast cancer who have previously responded to hormonal therapy.
4/28/2014 12:01 pm
(Yahoo! Finance) Apr 28, 2014 - Agenus Inc. announced today that the company has entered into a collaboration and license agreement with Merck for the discovery and development of therapeutic antibodies to immune checkpoints for the treatment of cancer.
3/20/2014 07:00 am
(GlaxoSmithKline) Mar 20, 2014 - GSK will continue the trial in order to assess the third co-primary endpoint, which is disease-free survival in a gene signature positive sub-population.
2/13/2014 12:00 pm
(Yahoo! Finance) Feb 13, 2014 - Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.
1/14/2014 11:04 am
(MarketWatch) Jan 14, 2014 - Phase 2 randomized trial will study Yervoy® and Prophage combination for metastatic melanoma; first checkpoint inhibitor combination trial with Prophage vaccine.
1/13/2014 11:05 am
(Yahoo! Finance UK) Jan 13, 2014 - 4-Antibody has a powerful platform for rapid discovery and optimization of fully-human antibodies against a wide array of molecular targets; lead programs target six immune checkpoint molecules; checkpoint antibodies have produced unprecedented results against a variety of cancers affecting a large number of patients; collaborations with the Ludwig Institute for Cancer Research and Memorial Sloan-Kettering Cancer Center.
11/5/2013 11:04 am
(AACR) Nov 4, 2013 - For children with central nervous system cancers, the presence of a specific genetic modification—hypermethylation of the TERT promoter—may help predict tumor progression and patient survival, according to results presented at the AACR special conference on Pediatric Cancer at the Crossroads: Translating Discovery Into Improved Outcomes, held Nov. 3-6.
9/17/2013 12:00 pm
(Reuters) Sep 17, 2013 - Biotechnology company Agenus Inc said its experimental brain cancer vaccine increased the survival of patients without their cancer worsening in a mid-stage trial, compared with the standard treatment.
9/5/2013 12:01 pm
(Bloomberg Businessweek) Sep 5, 2013 - Agenus Inc., a developer of treatments for cancer and infectious diseases, plummeted the most in four years after partner GlaxoSmithKline Plc’s (GSK) MAGE-A3 vaccine failed to help skin-tumor patients in a trial.
5/2/2013 12:01 pm
(NPR) May 2, 2013 - If you're under 21, you may soon have a hard time lighting up in New York City. Public health officials in New York want to raise the minimum age for buying cigarettes.
5/2/2013 11:04 am
(Boston Business Journal) May 1, 2013 - Agenus Inc. on Wednesday reported results from a mid-stage trial of a potential brain cancer vaccine showing big increases in both progression-free and overall survival.
2/13/2013 12:03 pm
(BloombergBusinessweek) Feb 12, 2013 - Ziopharm Oncology Inc, a developer of experimental cancer drugs, is in talks with potential partners to market its lead compound, palifosfamide, Chief Executive Officer Jonathan Lewis said.
12/13/2012 11:05 am
(ACCC Buzz) Dec 10, 2012 - The American College of Surgeons Commission on Cancer’s new Standard 3.2: Psychosocial Distress Screening continues to be a hot topic of discussion. Even a recent Wall Street Journal column, “To Treat the Cancer, Treat the Distress,” took note of the new mandate.
10/15/2012 12:01 pm
(New York Times) Oct 12, 2012 - For all his innate prudence, Scott now, at age 52, is suffering from Stage 4 prostate cancer, in part because he didn’t have health insurance. President Obama’s health care reform came just a bit too late to help Scott, but it will protect others like him — unless Mitt Romney repeals it.
10/12/2012 11:00 am
(Bloomberg Businessweek) Oct 11, 2012 - Obesity treatments, life-saving antibiotics and other drugs deemed to offer societal benefit despite their risks may get speedier U.S. approvals under plans being discussed to better balance innovation and safety.
6/19/2012 08:02 pm
6/18/2012 01:05 pm
[GlobeNewswire] - LEXINGTON, Mass. -- Agenus, Inc. , a biotechnology company working to develop treatments for cancers and infectious diseases, today announced that it is set to join the broad-market Russell 3000(R) Index, ...
6/7/2012 12:04 pm
(Reuters) June 7, 2012 - Patients who want an injectable form of Roche Holding AG's bone-strengthening drug Boniva may not be able to get it in the next few weeks because the company did not accurately forecast demand, federal officials said.
6/1/2012 04:01 pm
[GlobeNewswire] - LEXINGTON, Mass. -- Agenus Inc. invites investors and the general public to its 2012 Annual Shareholders Meeting at 5:00 p.m. ET on Wednesday, June 13th. The meeting will be held at the company's headquarters ...
5/17/2012 05:00 pm